US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aridis Pharmaceuticals Inc.

0.0001

+0.0000

Volume:160.00

Turnover:0.02

Market Cap:4.46K

PE:0.00

High:0.0001

Open:0.0001

Low:0.0001

Close:0.0001

Loading ...

Overview Company News Filings

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

Healios Ends Collaboration Talks with Nobelpharma on ARDS Therapy

Healios Advances MultiStem Approval for ARDS in Japan

3 US Penny Stocks With Market Caps Under $200M To Consider

Simply Wall St.

Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study

Healios Nears Japan Approval for ARDS Treatment

MT Newswires Live

Healios KK Advances ARDS Treatment Approval

Aridis Pharmaceuticals continuing to explore ‘multiple paths to monetize’ assets

Aridis Provides Corporate Update

THOMSON REUTERS

Aridis Provides Corporate Update

US Penny Stocks To Consider In December 2024

Simply Wall St.

Press Release: Edesa Biotech Reports Fiscal Year 2024 Results

XORTX Announces Presentation at the Rare and Genetic Disease Summit

SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial

InflaRx receives positive CHMP opinion for GOHIBIC for SARS-CoV-2-induced ARDS

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Press Release: Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ARDS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARDS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARDS\",,,,,undefined,":{"symbol":"ARDS","market":"US","secType":"STK","nameCN":"Aridis Pharmaceuticals Inc.","latestPrice":0.0001,"timestamp":1746820800000,"preClose":0.0001,"halted":0,"volume":160,"delay":15,"floatShares":37958700,"shares":44574000,"eps":-0.039914,"marketStatus":"Market Closed","change":0,"latestTime":"05-09 16:00:00 EDT Delay","open":0.0001,"high":0.0001,"low":0.0001,"amount":0.016,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.039914,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"exchange":"EXPERT","adjPreClose":0.0001,"volumeRatio":0.0318154697663079},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARDS\",,,,,undefined,":{"symbol":"ARDS","floatShares":37958700,"roa":"-4.40%","roe":"415.66%","lyrEps":-1.617428,"volumeRatio":0.0318154697663079,"shares":44574000,"dividePrice":0,"high":0.0001,"amplitude":0,"preClose":0.0001,"low":0.0001,"week52Low":0.000001,"pbRate":"-0.00","psRate":"0.00","week52High":0.08,"institutionHeld":0,"latestPrice":0.0001,"eps":-0.039914,"divideRate":0,"volume":160,"delay":15,"ttmEps":-0.039914,"open":0.0001,"prevYearClose":0.0001,"prevWeekClose":0.0001,"prevMonthClose":0.0001,"prevQuarterClose":0.0001,"fiveDayClose":0.0001,"twentyDayClose":0.0001,"sixtyDayClose":0.0001},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARDS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503162032","title":"InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503162032","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503162032?lang=en_us&edition=fundamental","pubTime":"2025-01-16 01:30","pubTimestamp":1736962200,"startTime":"0","endTime":"0","summary":"JENA, Germany, Jan.  15, 2025  (GLOBE NEWSWIRE) -- InflaRxN.V.(Nasdaq:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/15/3010292/0/en/InflaRx-Receives-European-Commission-Approval-for-GOHIBIC-vilobelimab-for-the-Treatment-of-SARS-CoV-2-Induced-Acute-Respiratory-Distress-Syndrome-ARDS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","SG9999002232.USD","LU0096364046.USD","LU0094547139.USD","BK4568","BK4581","BK4018","BK4559","SG9999014542.SGD","LU0237698245.USD","LU2552382058.USD","LU2242652126.USD","IE00BWXC8680.SGD","USA","IE00B1XK9C88.USD","LU0234570918.USD","LU0098860793.USD","LU1868836757.USD","SG9999001440.SGD","BK4534","ARDS","SG9999014559.SGD","BK4588","LU0234572021.USD","SG9999015341.SGD","BK4535","BK4550","BK4548","BK4504","SG9999014575.USD","BK4585","LU0061475181.USD","LU1066051498.USD","EC","LU1066053197.SGD","IE00BLSP4239.USD","LU1868836591.USD","LU1868836914.USD","LU2242646821.SGD","PG","LU0868494617.USD","BK4567","IE00B3T34201.USD","LU1929549753.HKD","LU0320765646.SGD","BK4533","LU0640476718.USD","BNTX","IE00BLSP4452.SGD","LU1585245621.USD"],"gpt_icon":0},{"id":"2503866041","title":"Healios Ends Collaboration Talks with Nobelpharma on ARDS Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2503866041","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503866041?lang=en_us&edition=fundamental","pubTime":"2025-01-15 15:30","pubTimestamp":1736926204,"startTime":"0","endTime":"0","summary":"Healios KK ( ($JP:4593) ) has shared an update. Healios K.K. announced the termination of its collaboration discussions with Nobelpharma for the de...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/healios-ends-collaboration-talks-with-nobelpharma-on-ards-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/healios-ends-collaboration-talks-with-nobelpharma-on-ards-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARDS","BK4139"],"gpt_icon":0},{"id":"2503604106","title":"Healios Advances MultiStem Approval for ARDS in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2503604106","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503604106?lang=en_us&edition=fundamental","pubTime":"2025-01-15 15:29","pubTimestamp":1736926191,"startTime":"0","endTime":"0","summary":"Healios KK ( ($JP:4593) ) has shared an update. Healios K.K. announced a significant step in their application for conditional and time-limited app...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/healios-advances-multistem-approval-for-ards-in-japan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/healios-advances-multistem-approval-for-ards-in-japan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARDS","BK4139"],"gpt_icon":0},{"id":"2503683454","title":"3 US Penny Stocks With Market Caps Under $200M To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=2503683454","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503683454?lang=en_us&edition=fundamental","pubTime":"2025-01-15 01:07","pubTimestamp":1736874443,"startTime":"0","endTime":"0","summary":"The U.S. stock market has shown resilience, with the Dow Jones Industrial Average rising on a softer-than-expected Producer Price Index report and a dip in oil prices. For those interested in exploring smaller or newer companies, penny stocks—despite their somewhat outdated name—remain an intriguing investment area. These stocks can offer a mix of affordability and growth potential, especially when backed by strong financials, making them appealing to investors seeking under-the-radar...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-veru/veru/news/3-us-penny-stocks-with-market-caps-under-200m-to-consider-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SB","BABB","TORO","BK4021","BK4209","ARDS","BK4563","BK4139"],"gpt_icon":0},{"id":"2503957305","title":"Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2503957305","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503957305?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:30","pubTimestamp":1736861400,"startTime":"0","endTime":"0","summary":"Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week. The FDA agreed to two additional protocol changes expected to accelerate enrollment in the NEPHRO CRRT study. SAN MATEO, Calif., Jan. 14, 2025 /PRNewswire/ --Talphera, Inc. , , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that following a meeting with the U.S. Food and Drug Administration , the agency has agreed to review a Prior Approval Supplement  requesting a reduction in the number of patients in the NEPHRO CRRT clinical study. A PAS is reviewed by the FDA within 30 days, and its approval by the agency is required before formally amending the study protocol.Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setting","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/talphera-announces-agreement-fda-prior-133000407.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/talphera-announces-agreement-fda-prior-133000407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ARDS","TLPH","IDE","BK4007"],"gpt_icon":0},{"id":"2494819013","title":"Healios Nears Japan Approval for ARDS Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2494819013","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494819013?lang=en_us&edition=fundamental","pubTime":"2024-12-27 07:32","pubTimestamp":1735255963,"startTime":"0","endTime":"0","summary":"Healios K.K  said it made progress on its application for conditional approval of its MultiStem ARDS treatment in Japan after agreeing with regulators on manufacturing details, according to a Thursday filing on the Tokyo Stock Exchange.Clinical aspects of the application will be discussed with regulators in mid-January 2025.Price : $167.00, Change: $+3.0, Percent Change: +1.83%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARDS","BK4139"],"gpt_icon":0},{"id":"2494004710","title":"Healios KK Advances ARDS Treatment Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2494004710","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494004710?lang=en_us&edition=fundamental","pubTime":"2024-12-26 09:22","pubTimestamp":1735176143,"startTime":"0","endTime":"0","summary":"Healios KK (JP:4593) has released an update. Healios KK has made progress in its application for conditional approval of its MultiStem product for ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/healios-kk-advances-ards-treatment-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/healios-kk-advances-ards-treatment-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARDS","BK4139"],"gpt_icon":0},{"id":"2492443525","title":"Aridis Pharmaceuticals continuing to explore ‘multiple paths to monetize’ assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2492443525","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492443525?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:11","pubTimestamp":1734700275,"startTime":"0","endTime":"0","summary":"Aridis Pharmaceuticals (ARDS) announced a corporate update on recent developments. The company said, “The Company continues to diligently explore m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aridis-pharmaceuticals-continuing-to-explore-multiple-paths-to-monetize-assets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aridis-pharmaceuticals-continuing-to-explore-multiple-paths-to-monetize-assets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARDS"],"gpt_icon":0},{"id":"2492488654","title":"Aridis Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2492488654","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492488654?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:00","pubTimestamp":1734699601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nTUA6M4HV8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARDS"],"gpt_icon":0},{"id":"2492973448","title":"Aridis Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2492973448","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492973448?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:00","pubTimestamp":1734699600,"startTime":"0","endTime":"0","summary":"LOS GATOS, Calif., Dec. 20, 2024  -- Aridis Pharmaceuticals, Inc.  , a biopharmaceutical company, today announced a corporate update on recent developments.The Company has substantially reduced its operational cash burn by delaying the expenses associated with SEC filings in favor of business development discussions with potential partners and investors. As a result of voluntary non-compliance, the Company was transitioned to and expects to continue to be listed on the OTC Expert Market until a positive outcome from the business development effort on one or more of its programs.The discussions with potential partners and investors to continue the development of AR-301 resulted in an investment proposal from a globally recognized private investment firm in an amount that the Company believes is sufficient to complete the second and final Phase 3 study and product approval. The Company is working closely with the investment firm to satisfy specific requirements for the closing of investm","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TdPij3p80iBZC60HHYbkng--~B/aD0zNjE7dz01Mzk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/de744cc0cc25204099101ccc021f87ba","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TdPij3p80iBZC60HHYbkng--~B/aD0zNjE7dz01Mzk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/de744cc0cc25204099101ccc021f87ba"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aridis-provides-corporate-130000046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4093","BNTX","BK4585","BK4551","ARDS","BK4548","BK4588","BK4139","BK4535","HAP","BK4568","ICU","BK4082","CF"],"gpt_icon":0},{"id":"2492617788","title":"US Penny Stocks To Consider In December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2492617788","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492617788?lang=en_us&edition=fundamental","pubTime":"2024-12-17 01:06","pubTimestamp":1734368801,"startTime":"0","endTime":"0","summary":"As the U.S. stock market experiences a rise in anticipation of the Federal Reserve's upcoming meeting, with the Nasdaq hitting record highs, investors are exploring diverse opportunities across various sectors. Penny stocks, though often seen as remnants of past market trends, continue to offer intriguing possibilities for those seeking growth at lower entry points. By focusing on smaller or newer companies with strong financials and potential for expansion, investors can uncover valuable opportunities within this segment of the market.Click here to see the full list of 720 stocks from our US Penny Stocks screener.NasdaqCM:VERU Debt to Equity History and Analysis as at Dec 2024. Overview: Duluth Holdings Inc. operates in the United States, selling casual wear, workwear, outdoor apparel, and accessories for men and women under the Duluth Trading brand, with a market cap of approximately $120.31 million.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_kZOVgp9mzpLivYgIet9SA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8045a103f8959173903f7a11497803b2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_kZOVgp9mzpLivYgIet9SA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8045a103f8959173903f7a11497803b2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/us-penny-stocks-consider-december-170641698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4109","DLTH","BK4213","VERU","BK4209","FSI","BABB","BK4139","ARDS","PVL"],"gpt_icon":0},{"id":"2491258568","title":"Press Release: Edesa Biotech Reports Fiscal Year 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2491258568","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491258568?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:30","pubTimestamp":1734125400,"startTime":"0","endTime":"0","summary":"TORONTO, Dec. 13, 2024  -- Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2024 and provided an update on its business.During the fiscal year, the company pivoted the in-house development of its anti-TLR4 drug candidate, EB05 , to a U.S. government-funded study investigating novel threat-agnostic host-directed therapeutics in patients with Acute Respiratory Distress Syndrome . Given this opportunity, Edesa is also amending a development and drug manufacturing project for the same asset that is supported by the Government of Canada. The company said that the goal is to maximize synergies between the two government-funded projects. For its anti-CXCL10 program, Edesa intends to manufacture EB06 and submit related data to the U.S. Food and Drug Administration as part of an investigational new drug  application. The manu","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARDS","BK4139","EDSA"],"gpt_icon":0},{"id":"2490381420","title":"XORTX Announces Presentation at the Rare and Genetic Disease Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2490381420","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490381420?lang=en_us&edition=fundamental","pubTime":"2024-12-12 22:17","pubTimestamp":1734013020,"startTime":"0","endTime":"0","summary":"CALGARY, Alberta, Dec.  12, 2024  (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (\"XORTX\" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/12/2996288/0/en/XORTX-Announces-Presentation-at-the-Rare-and-Genetic-Disease-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XRTX","GENE","SMMF","BK4211","BK4139","ARDS","BK4007","BK4121"],"gpt_icon":0},{"id":"2490300558","title":"SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2490300558","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490300558?lang=en_us&edition=fundamental","pubTime":"2024-12-11 19:30","pubTimestamp":1733916600,"startTime":"0","endTime":"0","summary":"U.S. total addressable market for five initial indications is $25 to $33 billion REMINDER: Business Update Conference Call begins at 4:30 p.m. Eastern time today DENVER , Dec.  11, 2024  (GLOBE NEWSWI","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/11/2995222/0/en/SeaStar-Medical-Projects-Multibillion-Dollar-Market-Potential-for-its-Selective-Cytopheretic-Device-in-Initial-Target-Indications.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BDD","SCD","ARDS"],"gpt_icon":0},{"id":"2489410952","title":"MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND","url":"https://stock-news.laohu8.com/highlight/detail?id=2489410952","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489410952?lang=en_us&edition=fundamental","pubTime":"2024-12-06 07:00","pubTimestamp":1733439600,"startTime":"0","endTime":"0","summary":"LA JOLLA, Calif., Dec.  05, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/05/2992777/7767/en/MediciNova-Presents-Study-Update-and-Interim-Analysis-of-Phase-2-3-Clinical-Trial-of-MN-166-ibudilast-in-ALS-COMBAT-ALS-Clinical-Trial-at-the-35th-International-Symposium-on-ALS-MN.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","LU0225283273.USD","LU2357305700.SGD","LU1162221912.USD","LU2271345857.HKD","LU2023251221.USD","BK4581","LU2028103732.USD","CAFS","ARDS","BK4127","LU1548497426.USD","LU2089284900.SGD","LU2111349929.HKD","LU1989772923.USD","BK4585","LU0267386448.USD","BK4588","BK4139","LU0971096721.USD","MNOV","IE00BKVL7J92.USD","BK4534","LU1668664300.SGD","LU1720051017.SGD","LU0158827781.USD","BK4516","LU1989772840.SGD","LU0106261372.USD","LU1363072403.SGD","LU1720051108.HKD","LU0106831901.USD","BK4504","LU2089283258.USD","LU0098860793.USD","LU0158827948.USD","LU0006306889.USD","LU0320765646.SGD","LU0314104364.USD","LU1074936037.SGD"],"gpt_icon":0},{"id":"2489693106","title":"CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2489693106","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489693106?lang=en_us&edition=fundamental","pubTime":"2024-12-05 11:58","pubTimestamp":1733371080,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, Dec. 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited , a clinical-stage biotechnology company specialising in cell therapeutics, has successfully completed its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers .The trial met its primary objective, with CYP-006TK found to be safe and well-tolerated – no participants withdrew from the trial due to adverse events, and no suspected serious adverse reactions were reported.Importantly, the trial also generated positive efficacy data, indicating improved wound healing for CYP-006TK compared to the standard of care control group.After 12 weeks, a decrease  of 181mm2 in the CYP-006TK group, and an increase  of 355mm2 in the standard of care control group.\"We are very pleased and encouraged by these results. First and foremost, the trial achieved its primary objective of safety. Furthermore, whilst the trial was not powered to show statistically significant efficacy, we believe there is a clear signal indicati","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EzHmLG1vxG4V34g7FQIT9Q--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/2f43514b2123eab06a02ca36395134ab","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EzHmLG1vxG4V34g7FQIT9Q--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/2f43514b2123eab06a02ca36395134ab"],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/cyp-006tk-demonstrates-safety-efficacy-035800693.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cyp-006tk-demonstrates-safety-efficacy-035800693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["CYP.AU","MCA.AU","BK4139","BK7067","BK7141","BK7501","ARDS","BK7508"],"gpt_icon":0},{"id":"2483028378","title":"InflaRx receives positive CHMP opinion for GOHIBIC for SARS-CoV-2-induced ARDS","url":"https://stock-news.laohu8.com/highlight/detail?id=2483028378","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483028378?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:55","pubTimestamp":1731675317,"startTime":"0","endTime":"0","summary":"InflaRx (IFRX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inflarx-receives-positive-chmp-opinion-for-gohibic-for-sars-cov-2-induced-ards?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inflarx-receives-positive-chmp-opinion-for-gohibic-for-sars-cov-2-induced-ards?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARDS","BK4139","BK4087","CHMP","IFRX"],"gpt_icon":0},{"id":"2483378245","title":"InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2483378245","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483378245?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:51","pubTimestamp":1731675060,"startTime":"0","endTime":"0","summary":"JENA, Germany, Nov.  15, 2024  (GLOBE NEWSWIRE) -- InflaRxN.V.(Nasdaq:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/15/2981948/0/en/InflaRx-Receives-Positive-CHMP-Opinion-for-GOHIBIC-Vilobelimab-for-the-Treatment-of-SARS-CoV-2-Induced-Acute-Respiratory-Distress-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU1914381329.SGD","LU2242652126.USD","BK4567","BK4139","BK4504","BNTX","LU2242646821.SGD","BK4548","LU0234572021.USD","LU0237698245.USD","LU1585245621.USD","LU0640476718.USD","LU1280957306.USD","BK4551","IE00BLSP4452.SGD","IE00BLSP4239.USD","BK4581","BK4588","SG9999014575.USD","LU0868494617.USD","ARDS","IE00B3T34201.USD","SG9999014559.SGD","LU1868836591.USD","BK4585","BK4559","IE000M9KFDE8.USD","LU1868836914.USD","LU0096364046.USD","IE00B1XK9C88.USD","LU2552382132.HKD","PG","LU1066051498.USD","BK4558","BK4535","LU1066053197.SGD","LU1868836757.USD","LU1430594728.SGD","CHMP","LU0094547139.USD","LU2552382058.USD","IE00BWXC8680.SGD","LU0124676726.USD","LU2552382215.SGD","SG9999002232.USD","LU1868837300.USD","USA","SG9999015341.SGD","LU0061475181.USD"],"gpt_icon":0},{"id":"2483868460","title":"Press Release: Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868460","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868460?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531900,"startTime":"0","endTime":"0","summary":"Five sites actively screening with multiple patients having completed the study; two additional institutions expected to begin screening in the fourth quarter totaling seven active sites. Cash and investments at September 30, 2024 of $11.1 million. Conference call and webcast to be held Wednesday, November 13, 2024 at 4:30 pm ET. SAN MATEO, Calif., Nov. 13, 2024 /PRNewswire/ -- Talphera, Inc. , , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2024 financial results and provided a corporate update.Dr. Shakil Aslam, Talphera Chief Medical Officer, added, \"I remain convinced that nafamostat, if approved, will provide the first FDA-approved regional anticoagulant for CRRT, potentially avoiding the risks of systemic anticoagulation that occurs with heparin. After engagement and discussion with numerous clinicians and the NEPHRO investigators, we have identifie","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IDE","BK4099","BK4139","03160","TLPH","BK4555","TM","BK4007","ARDS","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":39,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARDS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2023-11-03","symbol":"ARDS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1698984000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-07-19","symbol":"ARDS","reason":null,"defaultRemindTime":1689773400000,"announcedDate":"2023-07-18","type":"delisting","dateTimestamp":1689739200000},{"market":"US","date":"2023-06-08","symbol":"ARDS","fiscalQuarterEnding":"2023/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1686196800000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2023-05-22","symbol":"ARDS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1684728000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2022-11-21","symbol":"ARDS","fiscalQuarterEnding":"2022/09","expectedEps":-0.01,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1669006800000,"reportTimeType":"post","actualEps":-0.42}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARDS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARDS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ARDS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ARDS","date":"2023-07-17","current":-0.392816,"percent":0.924757,"low":-5.587062,"twenty":-3.267676,"median":-2.120819,"eighty":-0.574899,"high":-0.179871,"avg":-2.082391,"sd":1.334232,"marketCap":11557032},"quantilePoints":[{"date":"2020-05-15","current":-2.585527,"twenty":-3.96973,"median":-3.232041,"eighty":-1.812908,"marketCap":76741016},{"date":"2020-05-22","current":-2.525398,"twenty":-3.959148,"median":-3.214149,"eighty":-1.815082,"marketCap":74956341},{"date":"2020-05-29","current":-2.087963,"twenty":-3.953774,"median":-3.209683,"eighty":-1.818918,"marketCap":61972832},{"date":"2020-06-05","current":-2.029338,"twenty":-3.948194,"median":-3.20639,"eighty":-1.824682,"marketCap":60232774},{"date":"2020-06-12","current":-1.917799,"twenty":-3.944605,"median":-3.196724,"eighty":-1.827674,"marketCap":56922202},{"date":"2020-06-19","current":-2.146588,"twenty":-3.941093,"median":-3.180211,"eighty":-1.827907,"marketCap":63712890},{"date":"2020-06-26","current":-2.104498,"twenty":-3.937989,"median":-3.172894,"eighty":-1.833656,"marketCap":62463618},{"date":"2020-07-02","current":-1.903068,"twenty":-3.937632,"median":-3.142342,"eighty":-1.833867,"marketCap":56484957},{"date":"2020-07-10","current":-1.954177,"twenty":-3.927144,"median":-3.126811,"eighty":-1.835812,"marketCap":58001931},{"date":"2020-07-17","current":-2.062408,"twenty":-3.91005,"median":-3.090384,"eighty":-1.836285,"marketCap":61214345},{"date":"2020-07-24","current":-2.131556,"twenty":-3.902663,"median":-3.066025,"eighty":-1.838968,"marketCap":63266721},{"date":"2020-07-31","current":-2.104498,"twenty":-3.879729,"median":-3.042808,"eighty":-1.839758,"marketCap":62463618},{"date":"2020-08-07","current":-2.173646,"twenty":-3.873257,"median":-2.992872,"eighty":-1.842062,"marketCap":64515994},{"date":"2020-08-14","current":-2.387363,"twenty":-3.864987,"median":-2.97201,"eighty":-1.84574,"marketCap":57198827},{"date":"2020-08-21","current":-2.387363,"twenty":-3.86298,"median":-2.72954,"eighty":-1.850871,"marketCap":57198827},{"date":"2020-08-28","current":-2.718838,"twenty":-3.840258,"median":-2.696764,"eighty":-1.854068,"marketCap":65140630},{"date":"2020-09-04","current":-2.584758,"twenty":-3.833051,"median":-2.692903,"eighty":-1.854595,"marketCap":61928215},{"date":"2020-09-11","current":-2.532616,"twenty":-3.821667,"median":-2.685318,"eighty":-1.854595,"marketCap":60678943},{"date":"2020-09-18","current":-2.733735,"twenty":-3.805176,"median":-2.681593,"eighty":-1.863569,"marketCap":65497565},{"date":"2020-09-25","current":-2.676975,"twenty":-3.792411,"median":-2.675821,"eighty":-1.874837,"marketCap":64137642},{"date":"2020-10-02","current":-2.793326,"twenty":-3.787971,"median":-2.676975,"eighty":-1.878754,"marketCap":66925305},{"date":"2020-10-09","current":-2.767255,"twenty":-3.78257,"median":-2.685318,"eighty":-1.885901,"marketCap":66300668},{"date":"2020-10-16","current":-2.871912,"twenty":-3.776069,"median":-2.700215,"eighty":-1.898037,"marketCap":68808136},{"date":"2020-10-23","current":-2.893886,"twenty":-3.772054,"median":-2.726286,"eighty":-1.90419,"marketCap":69334615},{"date":"2020-10-30","current":-2.305425,"twenty":-3.760016,"median":-2.718838,"eighty":-1.905243,"marketCap":55235685},{"date":"2020-11-06","current":-2.532616,"twenty":-3.752915,"median":-2.692903,"eighty":-1.907627,"marketCap":60678943},{"date":"2020-11-13","current":-2.644349,"twenty":-3.752356,"median":-2.681593,"eighty":-1.912689,"marketCap":63355955},{"date":"2020-11-20","current":-2.90358,"twenty":-3.751073,"median":-2.675821,"eighty":-1.915274,"marketCap":64337526},{"date":"2020-11-27","current":-3.101986,"twenty":-3.748966,"median":-2.681593,"eighty":-1.916356,"marketCap":68733816},{"date":"2020-12-04","current":-3.100397,"twenty":-3.740715,"median":-2.696764,"eighty":-1.920056,"marketCap":68698586},{"date":"2020-12-11","current":-3.347974,"twenty":-3.728085,"median":-2.718838,"eighty":-1.923698,"marketCap":74184407},{"date":"2020-12-18","current":-3.043613,"twenty":-3.719708,"median":-2.733735,"eighty":-1.924095,"marketCap":67440370},{"date":"2020-12-24","current":-2.943673,"twenty":-3.713337,"median":-2.752357,"eighty":-1.924582,"marketCap":65225910},{"date":"2020-12-31","current":-2.757422,"twenty":-3.70546,"median":-2.762316,"eighty":-1.926458,"marketCap":61098962},{"date":"2021-01-08","current":-2.839191,"twenty":-3.704304,"median":-2.762141,"eighty":-1.927119,"marketCap":62910793},{"date":"2021-01-15","current":-3.225321,"twenty":-3.704304,"median":-2.767255,"eighty":-1.933132,"marketCap":71466661},{"date":"2021-01-22","current":-3.129924,"twenty":-3.700049,"median":-2.775593,"eighty":-1.937942,"marketCap":69352859},{"date":"2021-01-29","current":-3.188934,"twenty":-3.698164,"median":-2.793326,"eighty":-1.941007,"marketCap":70660396},{"date":"2021-02-05","current":-3.20715,"twenty":-3.694233,"median":-2.802849,"eighty":-1.951636,"marketCap":71064032},{"date":"2021-02-12","current":-3.670506,"twenty":-3.675065,"median":-2.839191,"eighty":-1.954177,"marketCap":81331074},{"date":"2021-02-19","current":-2.943673,"twenty":-3.67414,"median":-2.850087,"eighty":-1.960835,"marketCap":65225910},{"date":"2021-02-26","current":-2.866447,"twenty":-3.668824,"median":-2.866447,"eighty":-1.974247,"marketCap":63514737},{"date":"2021-03-05","current":-2.516659,"twenty":-3.667657,"median":-2.858714,"eighty":-1.980833,"marketCap":55764127},{"date":"2021-03-12","current":-3.506969,"twenty":-3.663411,"median":-2.866447,"eighty":-1.983039,"marketCap":77707412},{"date":"2021-03-19","current":-3.198065,"twenty":-3.65847,"median":-2.87545,"eighty":-1.989013,"marketCap":70862718},{"date":"2021-03-26","current":-2.952759,"twenty":-3.65705,"median":-2.880075,"eighty":-1.992834,"marketCap":65427225},{"date":"2021-04-01","current":-2.996391,"twenty":-3.656297,"median":-2.886437,"eighty":-1.993261,"marketCap":66918409},{"date":"2021-04-09","current":-2.815401,"twenty":-3.65308,"median":-2.883256,"eighty":-1.994031,"marketCap":62876357},{"date":"2021-04-16","current":-2.836774,"twenty":-3.649715,"median":-2.878988,"eighty":-1.997578,"marketCap":63353674},{"date":"2021-04-23","current":-2.944913,"twenty":-3.641999,"median":-2.883256,"eighty":-2.002364,"marketCap":65768752},{"date":"2021-04-30","current":-3.133529,"twenty":-3.62322,"median":-2.890814,"eighty":-2.004159,"marketCap":69981097},{"date":"2021-05-07","current":-2.816655,"twenty":-3.611554,"median":-2.892879,"eighty":-2.007015,"marketCap":62904357},{"date":"2021-05-14","current":-3.161731,"twenty":-3.611228,"median":-2.893886,"eighty":-2.012033,"marketCap":71834529},{"date":"2021-05-21","current":-2.931832,"twenty":-3.606715,"median":-2.899664,"eighty":-2.014329,"marketCap":66611221},{"date":"2021-05-28","current":-2.857671,"twenty":-3.600447,"median":-2.893886,"eighty":-2.017321,"marketCap":64926283},{"date":"2021-06-04","current":-2.981273,"twenty":-3.598105,"median":-2.893886,"eighty":-2.019714,"marketCap":67734513},{"date":"2021-06-11","current":-3.426239,"twenty":-3.588377,"median":-2.905456,"eighty":-2.022351,"marketCap":77844142},{"date":"2021-06-18","current":-3.282861,"twenty":-3.586939,"median":-2.907332,"eighty":-2.023325,"marketCap":74586595},{"date":"2021-06-25","current":-3.584449,"twenty":-3.586861,"median":-2.916417,"eighty":-2.023381,"marketCap":81438677},{"date":"2021-07-02","current":-3.702711,"twenty":-3.598105,"median":-2.923681,"eighty":-2.023902,"marketCap":84125591},{"date":"2021-07-09","current":-3.5622,"twenty":-3.600447,"median":-2.931832,"eighty":-2.025098,"marketCap":80933195},{"date":"2021-07-16","current":-2.892279,"twenty":-3.600447,"median":-2.929571,"eighty":-2.029338,"marketCap":65712587},{"date":"2021-07-23","current":-2.556083,"twenty":-3.588737,"median":-2.92228,"eighty":-2.031081,"marketCap":58074201},{"date":"2021-07-30","current":-2.46709,"twenty":-3.586939,"median":-2.914146,"eighty":-2.032344,"marketCap":56052275},{"date":"2021-08-06","current":-2.598017,"twenty":-3.586939,"median":-2.907332,"eighty":-2.054144,"marketCap":59026951},{"date":"2021-08-13","current":-2.255441,"twenty":-3.586548,"median":-2.899664,"eighty":-2.062408,"marketCap":54108038},{"date":"2021-08-20","current":-2.103126,"twenty":-3.584449,"median":-2.893886,"eighty":-2.062408,"marketCap":50453989},{"date":"2021-08-27","current":-2.208575,"twenty":-3.569617,"median":-2.892968,"eighty":-2.065174,"marketCap":52983715},{"date":"2021-09-03","current":-2.43119,"twenty":-3.569617,"median":-2.892101,"eighty":-2.066976,"marketCap":58324249},{"date":"2021-09-10","current":-2.314024,"twenty":-3.565712,"median":-2.890814,"eighty":-2.068132,"marketCap":55513442},{"date":"2021-09-17","current":-2.355032,"twenty":-3.563302,"median":-2.882246,"eighty":-2.073231,"marketCap":56497224},{"date":"2021-09-24","current":-2.232008,"twenty":-3.562349,"median":-2.875731,"eighty":-2.074819,"marketCap":53545877},{"date":"2021-10-01","current":-2.108984,"twenty":-3.561625,"median":-2.869864,"eighty":-2.078737,"marketCap":50594529},{"date":"2021-10-08","current":-1.991818,"twenty":-3.56,"median":-2.866447,"eighty":-2.066616,"marketCap":47783722},{"date":"2021-10-15","current":-2.062118,"twenty":-3.55628,"median":-2.852727,"eighty":-2.064621,"marketCap":49470206},{"date":"2021-10-22","current":-1.927377,"twenty":-3.552936,"median":-2.851863,"eighty":-2.060946,"marketCap":46237778},{"date":"2021-10-29","current":-2.050401,"twenty":-3.54501,"median":-2.848637,"eighty":-2.049229,"marketCap":49189126},{"date":"2021-11-05","current":-1.892227,"twenty":-3.540045,"median":-2.839191,"eighty":-2.037417,"marketCap":45394536},{"date":"2021-11-12","current":-1.039553,"twenty":-3.535858,"median":-2.83344,"eighty":-2.024799,"marketCap":40756704},{"date":"2021-11-19","current":-0.842396,"twenty":-3.535008,"median":-2.816655,"eighty":-2.021908,"marketCap":33026984},{"date":"2021-11-26","current":-0.856735,"twenty":-3.529087,"median":-2.806362,"eighty":-2.017919,"marketCap":33589146},{"date":"2021-12-03","current":-0.742026,"twenty":-3.524237,"median":-2.800578,"eighty":-2.010537,"marketCap":29091854},{"date":"2021-12-10","current":-0.820888,"twenty":-3.515406,"median":-2.793326,"eighty":-2.002588,"marketCap":32183742},{"date":"2021-12-17","current":-0.774288,"twenty":-3.509232,"median":-2.78446,"eighty":-1.992834,"marketCap":30356717},{"date":"2021-12-23","current":-0.946351,"twenty":-3.508124,"median":-2.773287,"eighty":-1.987272,"marketCap":37102655},{"date":"2021-12-31","current":-0.835227,"twenty":-3.507078,"median":-2.763568,"eighty":-1.971255,"marketCap":32745903},{"date":"2022-01-07","current":-0.616562,"twenty":-3.506856,"median":-2.759694,"eighty":-1.957517,"marketCap":24172941},{"date":"2022-01-14","current":-0.552038,"twenty":-3.501539,"median":-2.748337,"eighty":-1.935537,"marketCap":21643215},{"date":"2022-01-21","current":-0.573546,"twenty":-3.493391,"median":-2.733735,"eighty":-1.92659,"marketCap":22486457},{"date":"2022-01-28","current":-0.702594,"twenty":-3.491382,"median":-2.729679,"eighty":-1.918927,"marketCap":27545910},{"date":"2022-02-04","current":-0.85315,"twenty":-3.4899,"median":-2.718838,"eighty":-1.906174,"marketCap":33448605},{"date":"2022-02-11","current":-0.921259,"twenty":-3.487888,"median":-2.698489,"eighty":-1.890838,"marketCap":36118872},{"date":"2022-02-18","current":-0.777872,"twenty":-3.484012,"median":-2.681593,"eighty":-1.857586,"marketCap":30497258},{"date":"2022-02-25","current":-0.777872,"twenty":-3.483074,"median":-2.676975,"eighty":-1.851959,"marketCap":30497258},{"date":"2022-03-04","current":-0.63807,"twenty":-3.483074,"median":-2.665021,"eighty":-1.839639,"marketCap":25016184},{"date":"2022-03-11","current":-0.562792,"twenty":-3.479524,"median":-2.653689,"eighty":-1.833656,"marketCap":22064836},{"date":"2022-03-18","current":-0.587885,"twenty":-3.47762,"median":-2.644349,"eighty":-1.818918,"marketCap":23048619},{"date":"2022-03-25","current":-0.59147,"twenty":-3.477366,"median":-2.638047,"eighty":-1.809869,"marketCap":23189159},{"date":"2022-04-01","current":-0.566252,"twenty":-3.475679,"median":-2.616575,"eighty":-1.779813,"marketCap":23891861},{"date":"2022-04-08","current":-0.496303,"twenty":-3.465791,"median":-2.607105,"eighty":-1.773792,"marketCap":20940513},{"date":"2022-04-14","current":-0.604136,"twenty":-3.465415,"median":-2.602542,"eighty":-1.743755,"marketCap":25490292},{"date":"2022-04-22","current":-0.553791,"twenty":-3.462481,"median":-2.598017,"eighty":-1.725372,"marketCap":23366101},{"date":"2022-04-29","current":-0.524423,"twenty":-3.461698,"median":-2.585527,"eighty":-1.712043,"marketCap":22126990},{"date":"2022-05-06","current":-0.478274,"twenty":-3.457058,"median":-2.581707,"eighty":-1.700291,"marketCap":20179814},{"date":"2022-05-13","current":-0.39143,"twenty":-3.445523,"median":-2.570494,"eighty":-1.665546,"marketCap":16515585},{"date":"2022-05-20","current":-0.439786,"twenty":-3.440566,"median":-2.56819,"eighty":-1.645205,"marketCap":18940703},{"date":"2022-05-27","current":-0.452116,"twenty":-3.436897,"median":-2.558469,"eighty":-1.618092,"marketCap":19471751},{"date":"2022-06-03","current":-0.431566,"twenty":-3.433794,"median":-2.556083,"eighty":-1.598302,"marketCap":18586671},{"date":"2022-06-10","current":-0.600082,"twenty":-3.428639,"median":-2.553859,"eighty":-1.580133,"marketCap":25844324},{"date":"2022-06-17","current":-0.579531,"twenty":-3.421994,"median":-2.546545,"eighty":-1.56824,"marketCap":24959244},{"date":"2022-06-24","current":-0.513769,"twenty":-3.41313,"median":-2.540065,"eighty":-1.555467,"marketCap":22126990},{"date":"2022-07-01","current":-0.452116,"twenty":-3.400851,"median":-2.529007,"eighty":-1.539912,"marketCap":19471751},{"date":"2022-07-08","current":-0.505548,"twenty":-3.395701,"median":-2.523421,"eighty":-1.515025,"marketCap":21772958},{"date":"2022-07-15","current":-0.452116,"twenty":-3.393016,"median":-2.517718,"eighty":-1.495641,"marketCap":19471751},{"date":"2022-07-22","current":-0.460296,"twenty":-3.387105,"median":-2.515327,"eighty":-1.463335,"marketCap":19824012},{"date":"2022-07-29","current":-1.015207,"twenty":-3.385697,"median":-2.511586,"eighty":-1.408894,"marketCap":43722932},{"date":"2022-08-05","current":-0.920673,"twenty":-3.381415,"median":-2.506594,"eighty":-1.361051,"marketCap":39651566},{"date":"2022-08-12","current":-0.949445,"twenty":-3.379996,"median":-2.50282,"eighty":-1.359789,"marketCap":40890677},{"date":"2022-08-19","current":-0.68775,"twenty":-3.379213,"median":-2.487287,"eighty":-1.315925,"marketCap":31331817},{"date":"2022-08-26","current":-0.629466,"twenty":-3.377392,"median":-2.472034,"eighty":-1.259928,"marketCap":28676579},{"date":"2022-09-02","current":-0.586724,"twenty":-3.375179,"median":-2.468042,"eighty":-1.086252,"marketCap":26729403},{"date":"2022-09-09","current":-0.742148,"twenty":-3.374217,"median":-2.466333,"eighty":-1.015207,"marketCap":33810040},{"date":"2022-09-16","current":-0.664436,"twenty":-3.371854,"median":-2.461825,"eighty":-0.989367,"marketCap":30269722},{"date":"2022-09-23","current":-0.470157,"twenty":-3.365906,"median":-2.450968,"eighty":-0.946351,"marketCap":21418926},{"date":"2022-09-30","current":-0.36136,"twenty":-3.360417,"median":-2.439002,"eighty":-0.920673,"marketCap":16462480},{"date":"2022-10-07","current":-0.42807,"twenty":-3.357022,"median":-2.432056,"eighty":-0.90692,"marketCap":19501592},{"date":"2022-10-14","current":-0.41968,"twenty":-3.356667,"median":-2.428332,"eighty":-0.900123,"marketCap":19119360},{"date":"2022-10-21","current":-0.42807,"twenty":-3.355429,"median":-2.418104,"eighty":-0.878243,"marketCap":19501592},{"date":"2022-10-28","current":-0.418653,"twenty":-3.355255,"median":-2.405141,"eighty":-0.856735,"marketCap":19072556},{"date":"2022-11-04","current":-0.385263,"twenty":-3.352504,"median":-2.397513,"eighty":-0.835227,"marketCap":17551432},{"date":"2022-11-11","current":-0.355298,"twenty":-3.351704,"median":-2.387363,"eighty":-0.828058,"marketCap":16186321},{"date":"2022-11-18","current":-0.358423,"twenty":-3.351704,"median":-2.382754,"eighty":-0.817304,"marketCap":16328682},{"date":"2022-11-25","current":-0.570968,"twenty":-3.34872,"median":-2.372465,"eighty":-0.802965,"marketCap":18724320},{"date":"2022-12-02","current":-0.602688,"twenty":-3.345928,"median":-2.355032,"eighty":-0.788328,"marketCap":19764560},{"date":"2022-12-09","current":-0.729171,"twenty":-3.344766,"median":-2.343316,"eighty":-0.777872,"marketCap":23912448},{"date":"2022-12-16","current":-0.744363,"twenty":-3.344324,"median":-2.337457,"eighty":-0.777155,"marketCap":24410624},{"date":"2022-12-23","current":-0.78234,"twenty":-3.338852,"median":-2.321106,"eighty":-0.77286,"marketCap":25656064},{"date":"2022-12-30","current":-0.896273,"twenty":-3.337502,"median":-2.310151,"eighty":-0.767149,"marketCap":29392384},{"date":"2023-01-06","current":-1.040588,"twenty":-3.337502,"median":-2.304356,"eighty":-0.767149,"marketCap":34125056},{"date":"2023-01-13","current":-0.968431,"twenty":-3.337277,"median":-2.288331,"eighty":-0.770005,"marketCap":31758720},{"date":"2023-01-20","current":-0.896273,"twenty":-3.335635,"median":-2.284884,"eighty":-0.774288,"marketCap":29392384},{"date":"2023-01-27","current":-0.539207,"twenty":-3.330292,"median":-2.284733,"eighty":-0.767149,"marketCap":17682757},{"date":"2023-02-03","current":-0.522953,"twenty":-3.328325,"median":-2.278871,"eighty":-0.761383,"marketCap":17149708},{"date":"2023-02-10","current":-0.454897,"twenty":-3.321763,"median":-2.270384,"eighty":-0.75278,"marketCap":14917880},{"date":"2023-02-17","current":-0.455732,"twenty":-3.317149,"median":-2.266166,"eighty":-0.74688,"marketCap":14945280},{"date":"2023-02-24","current":-0.444491,"twenty":-3.309098,"median":-2.26141,"eighty":-0.742148,"marketCap":14576629},{"date":"2023-03-03","current":-0.397854,"twenty":-3.304161,"median":-2.253938,"eighty":-0.724102,"marketCap":13047229},{"date":"2023-03-10","current":-0.348863,"twenty":-3.302547,"median":-2.243725,"eighty":-0.716933,"marketCap":11440611},{"date":"2023-03-17","current":-0.409687,"twenty":-3.300826,"median":-2.228382,"eighty":-0.703292,"marketCap":13435272},{"date":"2023-03-24","current":-0.44005,"twenty":-3.30041,"median":-2.21654,"eighty":-0.695425,"marketCap":14431012},{"date":"2023-03-31","current":-0.34555,"twenty":-3.30041,"median":-2.214357,"eighty":-0.676093,"marketCap":11331952},{"date":"2023-04-06","current":-0.291753,"twenty":-3.29957,"median":-2.210892,"eighty":-0.664181,"marketCap":9567761},{"date":"2023-04-14","current":-0.253029,"twenty":-3.297412,"median":-2.208575,"eighty":-0.648107,"marketCap":8297832},{"date":"2023-04-21","current":-0.26293,"twenty":-3.296925,"median":-2.202343,"eighty":-0.63807,"marketCap":8622530},{"date":"2023-04-28","current":-0.208034,"twenty":-3.294155,"median":-2.191,"eighty":-0.630901,"marketCap":6822261},{"date":"2023-05-05","current":-0.198023,"twenty":-3.293462,"median":-2.183656,"eighty":-0.623732,"marketCap":6493955},{"date":"2023-05-12","current":-0.242028,"twenty":-3.292592,"median":-2.171452,"eighty":-0.616325,"marketCap":7937057},{"date":"2023-05-19","current":-0.224426,"twenty":-3.289772,"median":-2.160655,"eighty":-0.605474,"marketCap":7359816},{"date":"2023-05-26","current":-0.215128,"twenty":-3.284113,"median":-2.15585,"eighty":-0.602553,"marketCap":6533641},{"date":"2023-06-02","current":-0.338312,"twenty":-3.282139,"median":-2.149992,"eighty":-0.600025,"marketCap":10274881},{"date":"2023-06-09","current":-0.34335,"twenty":-3.279407,"median":-2.139426,"eighty":-0.591517,"marketCap":10101708},{"date":"2023-06-16","current":-0.330965,"twenty":-3.274532,"median":-2.132784,"eighty":-0.585754,"marketCap":9737325},{"date":"2023-06-23","current":-0.31576,"twenty":-3.271532,"median":-2.132417,"eighty":-0.583612,"marketCap":9289964},{"date":"2023-06-30","current":-0.268159,"twenty":-3.270406,"median":-2.131556,"eighty":-0.579531,"marketCap":7889513},{"date":"2023-07-07","current":-0.287006,"twenty":-3.270406,"median":-2.123811,"eighty":-0.577312,"marketCap":8443990},{"date":"2023-07-14","current":-0.432356,"twenty":-3.267931,"median":-2.121678,"eighty":-0.575421,"marketCap":12720346},{"date":"2023-07-17","current":-0.392816,"twenty":-3.267676,"median":-2.120819,"eighty":-0.574899,"marketCap":11557032}],"updateTime":1747001550457}}}